ABBV241122P143000
- 0.00
- 0.000.00%
AbbVie Newsroom
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Optimism Over Global Healthcare Sector Rises: Jefferies
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
Unpacking the Latest Options Trading Trends in AbbVie
Market Falls on Retail Results, Bitcoin Swells, All Eyes on Nvidia | Live Stock
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today
High Alpha Stocks That Are Rated 'Overweight' – MS
Overweight-rated Companies That Are Focused on 'Operational Efficiency' – MS
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
Where Will AbbVie Be in 5 Years?
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $195
AbbVie Snaps Eight Straight Sessions of Losses
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA